Assertio Holdings (ASRT) Net Income towards Common Stockholders (2019 - 2026)

Assertio Holdings' (ASRT) quarterly Net Income towards Common Stockholders came in at -$18.9 million in Q1 2026, down 39.72% year-on-year from -$31.3 million in Q1 2025, and down 58.56% quarter-over-quarter from -$11.9 million in Q4 2025.

Assertio Holdings (ASRT) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends

Assertio Holdings has disclosed Net Income towards Common Stockholders across 8 years of filings, most recently posting -$18.9 million for Q1 2026.

  • Net Income towards Common Stockholders for Q1 2026 came in at -$18.9 million, down 39.72% year-over-year; the trailing twelve-month figure through Mar 2026 was -$35.7 million (down 16.55% YoY), and the FY2025 annual result was -$30.3 million, down 40.27% from the prior year.
  • Net Income towards Common Stockholders came in at -$18.9 million for Q1 2026 at Assertio Holdings, down from -$11.9 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $88.6 million in Q4 2022 to a low of -$279.5 million in Q3 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$3.6 million (2024), against an average of -$17.2 million.
  • Across the five-year window, Net Income towards Common Stockholders jumped 1811.83% in 2022 and slumped 6797.27% in 2023, its largest moves.
  • Assertio Holdings' Net Income towards Common Stockholders stood at $88.6 million in 2022, then sank by 164.78% to -$57.4 million in 2023, then jumped by 81.62% to -$10.5 million in 2024, then declined by 12.73% to -$11.9 million in 2025, then plunged by 58.56% to -$18.9 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$18.9 million (Q1 2026), -$11.9 million (Q4 2025), and $11.4 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Teva Pharmaceutical Industries 38.34 Bn 34.60 Bn 1.97 Bn 366.00 Mn
2 Zoetis 33.27 Bn 31.33 Bn 1.62 Bn 601.00 Mn
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn 274.90 Mn
4 Aurora Cannabis 17.11 Bn 17.03 Bn 33.43 Mn 1.99 Mn
5 Neurocrine Biosciences 16.37 Bn 15.05 Bn 800.70 Mn 197.90 Mn
6 Elanco Animal Health 11.78 Bn 11.35 Bn 785.00 Mn 57.00 Mn
7 Alkermes 7.05 Bn 6.54 Bn -116.06 Mn -66.53 Mn
8 Lantheus Holdings 6.49 Bn 5.99 Bn 230.92 Mn 118.42 Mn
9 Hims & Hers Health 6.19 Bn 5.44 Bn 396.79 Mn -92.12 Mn
10 Assertio Holdings 150.78 Mn 79.21 Mn 7.22 Mn -18.86 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -18.86 Mn
Dec 31, 2025 -11.89 Mn
Sep 30, 2025 11.45 Mn
Jun 30, 2025 -16.35 Mn
Mar 31, 2025 -13.50 Mn
Dec 31, 2024 -10.55 Mn
Sep 30, 2024 -2.92 Mn
Jun 30, 2024 -3.63 Mn
Mar 31, 2024 -4.48 Mn
Dec 31, 2023 -57.39 Mn
Sep 30, 2023 -279.54 Mn
Jun 30, 2023 8.47 Mn
Mar 31, 2023 -3.48 Mn
Dec 31, 2022 88.59 Mn
Sep 30, 2022 4.17 Mn
Jun 30, 2022 7.83 Mn
Mar 31, 2022 9.06 Mn
Dec 31, 2021 4.63 Mn
Sep 30, 2021 3.74 Mn
Jun 30, 2021 -14.17 Mn